Proceedings of the National Academy of Sciences · 1984 · 64 citations · 7 references
MedicineEndocrinologyOncologyEndocrine OncologyProstate DiseaseReproductive EndocrinologyAndrogen PhysiologyHormonal Cancer TherapyHormonal TherapyProstate CancerProstate DisordersProstate SurgeryAndrogen PharmacologyAntiandrogen InteractionsLuteinizing Hormone-releasing Hormone AgonistsLuteinizing Hormone-releasing Hormone Analog TherapyLuteinizing Hormone-releasing Hormone TherapyProstate AndrogensProstate Cancer Hormonal TherapyProstate Cancer Hormone Therapy
Although castration levels of serum androgens are consistently achieved after 2-3 weeks of treatment with luteinizing hormone-releasing hormone (LHRH) agonists, the administration of these peptides alone in adult men is always accompanied by a transient increase in plasma testosterone and dihydrotestosterone levels, which lasts for 5-15 days at the beginning of treatment and is accompanied by disease flare-up in some cases, thus seriously limiting the acceptability of this otherwise efficient and well-tolerated treatment. The present data show that the simultaneous administration of a pure antiandrogen neutralizes the influence of the transient increase in serum androgens on prostate cancer, as indicated by the 60% decrease in serum prostatic acid phosphatase observed within 5 days of combined treatment with an LHRH agonist and a pure antiandrogen. The addition of a pure antiandrogen thus makes fully acceptable the use of LHRH agonists as an advantageous substitute for surgical castration and estrogens in the treatment of prostate cancer.
7
ENDOCRINE CONTROL OF PROSTATIC CARCINOMA
Reed M. Nesbit · Journal of the American Medical Association · 1950 · 374 citations
Medicine, Endocrinology, Oncology +11
Fernand Labrie, A. Dupont, A. Bèlanger et al. · PubMed · 1982 · 274 citations